EEP 143 Lecture 25 Valuing Biodiversity - PowerPoint PPT Presentation

1 / 39
About This Presentation
Title:

EEP 143 Lecture 25 Valuing Biodiversity

Description:

EEP 143 Lecture 25 Valuing Biodiversity Re-visit 3 cases introduced last lecture Analyze alternate outcomes What should we wish for? Access and Benefit Sharing: Results? – PowerPoint PPT presentation

Number of Views:157
Avg rating:3.0/5.0
Slides: 40
Provided by: BrianW77
Category:

less

Transcript and Presenter's Notes

Title: EEP 143 Lecture 25 Valuing Biodiversity


1
EEP 143 Lecture 25Valuing Biodiversity
  • Re-visit 3 cases introduced last lecture
  • Analyze alternate outcomes
  • What should we wish for?

2
Access and Benefit Sharing Results?
  • Initial optimism
  • LDC countries too small/poor to get most of
    consumer benefits from medical or agricultural
    innovations
  • Instead get benefits via royalties or other
    consideration
  • E.g. Debt forgiveness swap for Amazon forest
    conservation
  • Merck-INBIO Costa Rican deal 1M plus royalties
    as first success

3
Are deals for access to indigenous
products/knowledge sufficient to conserve
biodiversity?
  • Logic
  • Maybe 1/3 of drugs derive from plants
  • Some drugs are worth billions
  • A royalty of 10 would be worth hundreds of
    millions

4
Are deals for access to indigenous
products/knowledge sufficient to conserve
biodiversity?
  • How as access and benefit sharing worked out?
  • INBIO no news of successful products
  • Read Cori Hayden (also Shane Greene if interested)

5
Case Studies (Koo and Wright 1999)
  • Rosy Periwinkle
  • Pacific Yew
  • Rice (Oryza nivara) resistant to brown plant
    hopper

6
Rosy Periwinkle
  • Used in indigenous medicine
  • Specimens collected in Madagascar
  • Contains 2 alkaloids
  • vinblastine increases remission rate from
    Hodgkins disease from 20 to 80
  • vincristine provides 90 remission rate for
    childhood leukemia
  • Drugs sold by Eli Lilly (Velban, Oncovin) for
    more than 200M per year

7
(No Transcript)
8
Rosy Periwinkle
  • 15 tons of leaves yield 1 oz of Vincristine
  • Reports of depletion of the plant in Madagascar
  • Scant reward to Madagascar
  • What should we conclude?

9
Pacific yew tree
  • weed tree of pacific Northwest forests
  • Historical use is now gone (what was it?)
  • In 1986, bark extract (initially called Taxol)
    found by novel screening method to be useful for
    combating ovarian cancer
  • 4 to 6 trees give enough bark for 1 patient

10
Pacific yew tree
  • CRADA auction
  • Bristol-Myers Squibb was high bidder
  • Agreed to invest 100M in trials
  • Exclusive partnership with National cancer
    Institute
  • Cooperation with Forest Service, BLM

11
IP note
  • BMS purchased the trademark of a cough remedy
    called and stopped others using name now
    generically paclitaxel

12
Pacific yew tree
  • Initially BMS had orphan drug protection, lt
    200,00 women as potential users
  • Later Taxol found effective against breast
    cancer, 1B market
  • Abandoned orphan status
  • Now one of largest drugs on market

13
(No Transcript)
14
Pacific yew tree
  • Controversies
  • Contract collectors using live trees not just
    dead trees
  • Complaints of excess profits to BMS
  • What do you think?

15
Pacific yew tree
  • Substitutes found
  • Yew in Nepal also useful
  • Needles can be used for extract
  • Yew farms
  • Bacterial source?
  • Synthesis?

16
What do these examples tell us?
  • Rosy Periwinkle
  • Should Madagascar have been compensated?
  • Was it indigenous to Madagascar?
  • Seems do, despite my statement referencing Myers
    and Simon
  • (hazards of writing in interdisciplinary field)
  • Where did the useful knowledge come from?
  • Targeted by pharma because of its use for an
    anti-diabetic tea (Goldman 1994) in Jamaica and
    Philippines
  • Should Jamaica and Philippines be compensated?

17
What does Rosy Periwinkle example tell us?
  • More generally, center of origin is not
    necessarily center of diversity or knowledge
  • May be many national centers of either
  • Wheat is another example of this (Ethiopia v.
    Middle East)

18
What does Pacific Yew example tell us?
  • Contract failure in harvesting?
  • Commitment problem for public sector when
    probability of success is low, so profits if
    successful must be high
  • Enforceability of fair pricing language in
    CRADA
  • Effectiveness of orphan drug provisions as
    alternative to patents
  • Low ex ante value of prospect with huge value ex
    post (confirmed by open auction)

19
What do these examples tell us?
  • What should we wish for?
  • An indispensable plant?
  • A plant for which a good substitute can be found?
  • What are implications for conservation?

20
What do these examples tell us? What should we
wish for?
  • An indispensable plant?
  • Rosy Periwinkle was indispensable plant
  • So Madagascar plants were by some accounts
    practically eliminated
  • Say there was full compensation to Madagascar?
  • Is this conservation??

21
What do these examples tell us? What should we
wish for?
  • A plant for which a good substitute can be found?
  • The pacific yew bark had (eventually) good
    substitutes
  • Himalayan yew is this a good solution?
  • Yew farms for needles
  • So one less reason to preserve the Pacific Yew?
  • Is this sustainable conservation?

22
Third example Oryza nivara and resistance to the
brown plant hopper
  • Brown plant hopper spread in HYV (high yield)
    rice in Asia in 1960s-1970s
  • Carrier of grassy stunt virus
  • Search of ex situ IRRI gene bank yielded one
    virus resistant variety, Oryza nivara, among 6700
    breeding lines and wild and farmer varieties
  • Used to create, via crossbreeding and an embryo
    rescue technique, a resistant commercial variety
    in 1976

23
Oryza nivara and resistance to the brown plant
hopper
  • Resistance (of the rice) to the virus broke down
    in a decade
  • New resistant varieties were found
  • Were these indispensable?

24
Oryza nivara and resistance to the brown plant
hopper
  • New resistant varieties were found
  • Were these indispensable?
  • No, reduced pesticide use solved the problem by
    allowing plant hopper predators to survive and
    control the pest
  • Change of management substituted for genetic
    resources in this case (and reduced pesticide
    harm)

25
Can payments by Pharma save (all) the Amazon
forest?
  • An intellectual challenge from a simple model
    (Simpson et al. 1996)
  • Consider the search for one trait (e.g. malaria
    control) in a forest
  • Assume each trees probability of having the
    trait is independent (favors high value)
  • Assume a constant cost of search per tree

26
Can payments by Pharma save (all) the Amazon
forest?
  • Assume 1 million trees
  • 2 extreme cases
  • Each tree has a very high probability of having
    the trait
  • Is this good for the value of the forest?
  • Is this good for the case for conserving all the
    trees?

27
Can payments by Pharma save (all) the Amazon
forest?
  • Assume n1 million trees
  • 2 extreme cases
  • Each tree has a very high probability p of having
    the trait
  • Is this good for the value of the forest?
  • Is this good for the case for conserving all the
    trees?

28
1. Each tree has a very high probability p of
having the trait
  • Marginal value is p(1-p)(n-1) V ,
  • (probability marginal tree has the trait) x
  • (probability all other trees do not) x V
  • Total value of trees, V, may be high , but
    marginal value is very low p(1-p)(n-1) V.

29
Second extreme case
  • 2. Each tree has a very high probability p of
    having the trait
  • Is this good for the value of the forest?
  • Is this good for the case for conserving all the
    trees?

30
2. Each tree has a very low probability p of
having the trait
  • Marginal value is p(1-p)(n-1) V,
  • (probability marginal tree has the trait) x
  • (probability all other trees do not) x V
  • Total value of trees, V, may be high , but
    marginal value is again very low
  • p(1-p)(n-1) V.

31
Results can differ if number of species increases
with area of forest
  • But relation is increasing but CONCAVE, according
    to ecologists
  • Same general dilemma seems to arise
  • This message was not well received by ecologists
    initially!

32
What to conclude?
  • If wealthy countries want the Amazon conserved,
    they will have to
  • pay for conservation (as in debt-for nature
    swaps)
  • Medical beneficiaries will have to share some of
    their surplus with Brazil, beyond the drug price

33
What about drugs for the poor?
  • Consider linear demand for drug, with demand
    proportional to income
  • Will a monopolist who cannot price discriminate
    serve all who need the drug?

34
What about drugs for the poor?
  • Consider linear demand for drug, with demand
    proportional to income
  • Will a monopolist who cannot price discriminate
    serve all who need the drug?

35
What about drugs for the poor?
  • Consider linear demand for drug, with demand
    proportional to income
  • Will a monopolist who cannot price discriminate
    serve all who need the drug?
  • Case for subsidy?
  • Case for price discrimination?
  • Effect of TRIPS?

36
My research
  • EBI projects
  • Effect of IPRs on biofuels research
  • Overview of relevant economics of IPR
  • Patent landscape for biofuels
  • Survey of effects of IPR on work of EBI scientists

37
My research
  • EBI projects
  • 2. Effect of biofuels on food security
  • New interaction of food, energy markets
  • Estimation of effects of energy disturbances on
    food production variation, commodity markets and
    commodity stocks levels and variation

38
My research
  • Patenting of research tools
  • Model of energy resources exploration, resources
    and reserves
  • Methods of analysis of stochastic models of
    commodity markets and price expectations

39
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com